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Chronic hepatitis B (CHB) leads to cirrhosis and hepatocellular carcinoma (HCC).  With a cohort of 
1,206 CHB patients who visited Okayama University Hospital and related hospitals in 2011 and 2012,  
we compared the incidence rates of HCC among the patients grouped by age,  hepatitis B virus (HBV) 
DNA,  hepatitis B e antigen (HBeAg),  and treatment.  HCCs were observed in 115 patients with the 
median observation period of 1,687 days.  Among the HCC patients aged 35 years,  HBV DNA 4 log 
copies/mL and positive HBeAg at diagnosis (n＝184),  the HCC incidence rate was 8.4  at 5 years in 
the entecavir (ETV)-treated patients,  21.8  in the lamivudine (LVD)-treated patients,  and 26.4  among 
the patients not treated with drugs.  The cumulative HCC incidence was signiﬁcantly reduced in the 
ETV-treated patients compared to those treated with LVD or not treated (p＝0.013).  Among the 
patients aged 35 years with HBV DNA 4 log copies/mL and negative HBeAg (n＝237),  the cumula-
tive HCC incidence was 14.6  in 5 years in ETV group and 13.9  among those not treated with a drug 
(p＞0.05).  Only small numbers of HCCs occurred in other patients.  In CHB patients aged 35 years 
with HBV DNA 4 log copies/mL and positive HBeAg,  ETV treatment is recommended for the sup-
pression of HCC development.
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A pproximately 350-400 million people worldwide have a chronic hepatitis B (CHB) infection,  and the majority of them live in the Asia-Paciﬁc region [1,  2].  CHB patients with active hepatitis are at risk of 
developing liver cirrhosis,  liver failure,  and hepato-
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cellular carcinoma (HCC).  The incidence of HCC 
development among individuals with a CHB infection 
is 0.8  annually,  approx.  100-fold higher than the 
rate among healthy people.  In addition,  every year 
approx.  500,000 patients around the world die from 
hepatitis B virus (HBV)-related liver disease [3].
　 Several studies have shown that persistent eleva-
tions of HBV-DNA and alanine aminotransferase 
(ALT) in serum and active hepatitis in laparoscopic 
ﬁndings are signiﬁcantly associated with rapid disease 
progression and HCC development [4-6].  Antiviral 
treatment,  including treatment with interferon (IFN) 
or nucleos(t)ide analogs (Nucs),  is designed to coun-
teract active hepatitis and to suppress the develop-
ment of liver failure and HCC [7].  Nucs are now also 
used for post-liver transplantation antiviral prophy-
laxis [8-10].
　 In 2004,  Liaw et al.  reported the HCC-suppressing 
eﬀect of Nucs in a randomized controlled trial.  The 
lamivudine (LVD)-treated group showed a signiﬁcantly 
lower HCC development rate than the placebo group,  
with the observation period of 32.4 months (3.9  vs. 
7.4 ,  p＝0.047) [11].  Several cohort studies have 
shown that LVD treatment signiﬁcantly reduced mor-
tality and prevented HCC development compared to 
patients not treated with Nucs [12-14].
　 After the introduction of LVD for the treatment of 
CHB in the late 1990s,  4 additional Nucs,  i.e.,  adefo-
vir,  telbivudine,  entecavir,  and tenofovir,  were 
approved worldwide.  Adefovir monotherapy lead to a 
high incidence of drug-resistant mutations and renal 
dysfunction,  and thus nowadays adefovir is prescribed 
in combination with other Nucs [15].
　 Entecavir (ETV) and tenofovir are more potent 
than LVD in terms of suppressing HBV replication,  
with a very low risk of drug-resistant mutations [16].  
Thus,  ETV and tenofovir are currently recommended 
as ﬁrst-line Nucs treatment for patients with active 
CHB [17].  However,  it is not yet known whether 
ETV or tenofovir is as eﬀective at reducing the risk 
of HCC development as LVD.
　 Entecavir (ETV) is a relatively new antiviral Nucs 
that eﬃciently suppressed the HBV DNA production 
and improved the hepatitis of nucleos(t)ide-naïve CHB 
patients [18].  In addition,  drug-resistant mutations to 
long-term ETV treatment remained rare.
　 In the present study we examined whether long-
term ETV treatment would reduce the HCC risk in 
HBV-infected patients compared with Nucs-naïve 
patients.  We suspected that the risk of hepatocar-
cinogenesis would diﬀer by patient age,  hepatitis B 
envelope antigen (HBeAg) status,  HBV DNA titer,  
and ﬁbrosis stage in chronic HBV infection.  We then 
investigated who should be treated with ETV by prior-
ity among CHB patients.
Patients and Methods
　 Patients and design. We enrolled 1,875 CHB 
patients who visited Okayama University Hospital and 
related hospitals in 2011 and 2012.  These patients 
were chronically monoinfected with HBV and were 
conﬁrmed as being hepatitis B surface antigen 
(HBsAg)-positive for at least 6 months.  Within this 
patient group,  we excluded 669 patients: those whose 
observation period among the non-treated patients or 
the treatment period in Nucs-treated patients was 
＜180 days,  those who had a co-infection with hepati-
tis C virus or human immunodeﬁciency virus,  those 
who underwent a consultation for the treatment of 
HCC,  and those who had been treated with an immu-
nosuppressive drug or anticancer drug.  The remain-
ing 1,206 patients were included in the study.
　 Among the patients without Nucs treatment,  the 
observation period was calculated from the patientʼs 
ﬁrst visit to the development of HCC or to the end of 
the observation.  Among the patients treated with 
Nucs,  the observation period was calculated from the 
introduction of Nucs treatment to the development of 
HCC or the end of observation.
　 In accord with the Japanese treatment guidelines 
for HBV infection,  nucleoside analogues were initi-
ated in patients who had both an abnormal ALT level 
(deﬁned as ALT 45) and an HBV DNA level of 4 log 
copies/mL or more.  LVD was administered to patients 
who were treated with a nucleoside analogue before 
ETV was approved in Japan in 2006.  Patients who 
developed LVD- or ETV-resistant HBV received 
adefovir (ADV) when their serum HBV DNA level 
increased by 1 log copies/mL over the minimal titer 
according to the guideline.
　 We deﬁned the LVD group as patients treated with 
LVD monotherapy or LVD combined with ADV 
throughout their treatment history.  The ETV group 
was deﬁned as the patients treated with ETV mono-
therapy or ETV combined with ADV at the end of the 
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follow-up.  All study protocols were approved by the 
Ethics Committee at the Okayama University Hospital 
and aﬃliated hospitals.
　 Clinical data collection and follow-up. All 
patients were followed at＜6-month intervals,  during 
which biochemical and HBV virological markers,  
blood counts and tumor markers (e.g.  alpha-fetopro-
tein [AFP] and des-c-carboxylprothrombin) were 
monitored.  All patients also underwent ultrasonogra-
phy,  dynamic computed tomography (CT) or dynamic 
magnetic resonance imaging (MRI) every 3-6 months.  
A viral response in the ETV or LVD group was 
deﬁned as a reduction in the HBV DNA level to below 
400 copies/mL.  In accord with the Japanese clinical 
practice guidelines for HCC,  HCC was diagnosed 
predominantly via imaging,  including dynamic CT,  
MRI,  and/or digital subtraction angiography.  When a 
hepatic nodule did not show typical imaging features,  
the diagnosis was conﬁrmed by a ﬁne-needle aspiration 
biopsy followed by histological examination.
　 HBV status. Each patientʼs HBV-DNA level 
was measured using a transcription-mediated ampliﬁca-
tion (TMA) assay (SRL,  Tokyo,  Japan),  a polyerase 
chain reaction (PCR) assay (Amplicor HBV Monitor 
assay; Roche Diagnostics,  Tokyo,  Japan) or a real-
time PCR assay (COBAS TaqMan HBV Test; Roche 
Diagnos tics).
　 HBsAg,  HBeAg,  hepatitis B surface antibody 
(HBsAb),  and hepatitis B envelope antibody (HBeAb) 
were routinely measured using a commercially avail-
able chemiluminescent enzyme immunoassay (CLEIA) 
system (Lumipulse System; Fujirebio,  Tokyo,  Japan) 
or an enzyme-linked immunosorbent assay (ELISA) 
(Sysmex,  Kobe,  Japan).
　 Statistical analysis. Statistical comparisons 
were performed using JMP version 7.0.1 software 
(SAS Institute,  Cary,  NC,  USA).  Categorical data 
were compared using chi-square or Fisherʼs exact 
tests.  Continuous variables were compared using 
Studentʼs t-test or the Wilcoxon rank sum test.  We 
compared the cumulative incidence of HCC using the 
log-rank test,  and we used a Cox proportional hazard 
regression analysis to assess the variables that were 
signiﬁcantly associated with the development of HCC.  
Deaths before HCC development were censored.
　 The incidence rates of HCC were compared among 
the patients grouped by age,  HBV DNA,  HBe anti-
gen,  and treatment.  The cumulative HCC incidences 
were analyzed with the Kaplan-Meier method and log 
rank test.  Signiﬁcance was deﬁned as p＜0.05 for all 
two-tailed tests.
Results
　 Patient characteristics. The patient charac-
teristics at the baseline are shown in Table 1.  The 
median age of the 1,206 patients was 49 years among 
the 670 males (55 ) and 536 females (45 ).  Nucs 
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Table 1　 Patient characteristics and demographics (n＝1,206)
Age† years 49 (11-88)
Sex male/female 670/536
Observation period† days 1,687 (182-11,752)
Nuc. ETV/LVD/Not treated 433/116/657
HCC 115
HBV genotype A/B/C/D 21/30/483/2
T. Bil† mg/dL 0.8 (0.1-27.5)
Albumin† g/dL 4.2 (2.0-5.7)
Platelet† ×104/mm3 17.9 (1.7-46.3)
PT† % 90 15　～189
ALT† IU/L 43 1　～13,320
AST† IU/L 36 1　～6,325
GGT† IU/L 31 4　～5,213
AFP† ng/mL 4 0　～8,912
DCP† mAU/mL 18 0　～62,600
HBV DNA† log copies/mL 5.4 -　～＞9.1
HBeAg ＋/－ 308/580
†median (range).  Nucs.,  nucleoside analogue; ETV,  entecavir; LVD,  lamivudine; HCC,  hepatocellular carcinoma; HBV,  hepatitis B 
virus.
were administered to 549 patients: 433 patients were 
treated with a regimen that included ETV,  and 116 
patients were treated with a regimen that included 
LVD.  HCCs were observed in 115 patients,  with the 
mean observation period of 1,687 days.
　 Change of laboratory data 1 year after the 
initiation of Nucs treatment. The baseline 
parameters of the patients grouped by treatment 
(ETV regimen,  LVD regimen,  and no treatment) are 
shown in Table 2.  Most of the parameters examined 
diﬀered signiﬁcantly among the treatment groups.  In 
general,  the patients in the 2 Nucs-treated groups 
were older and more likely to be male,  and to have 
high serum HBV DNA,  a high AFP titer and poor 
hepatic reserve compared to the patients in the non-
treated group.
　 One year after the initiation of Nucs treatment,  
the patientsʼ laboratory data and viral markers were 
signiﬁcantly improved (Table 3).  Because the ETV 
groupʼs baseline total bilirubin (T. Bil),  aspartate 
aminotransferase (AST),  ALT,  and AFP values were 
lower and their baseline albumin and platelet count 
values were higher compared to those of the LVD 
group,  these parameters improved less in the ETV 
group.  Of note,  HBV DNA became undetectable 
after 1 year of ETV treatment in 85 of the 279 
patients assessed; in the other 118 patients,  HBV 
DNA was not measured after 1 year of ETV treat-
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Table 2　 Patient characteristics and demographics by treatment groups
ETV LVD Not treated
P-value:
(LVD vs.
Not-treated)
P-value
(ETV vs.
Not- treated)
No. of patients 433 116 657
Age† years 52 50 46 ＜0.0005 ＜0.0001
Sex male/female 269/164 70/46 331/326 ＜0.05 ＜0.0001
Observation period† days 1,197 2,714.5 1,978 ＜0.05 ＜0.0001
HCC 32 39 44 ＜0.0001 n.s.
HBV DNA† Log copies/mL 6.7 6.9 3.8 ＜0.0001 ＜0.0001
HBV genotype B/C 9/245 1/60 20/178 ＜0.05 ＜0.0001
HBeAg ＋/－ 145/158 50/24 113/398 ＜0.0001 ＜0.0001
T. Bil† mg/dL 0.8 0.9 0.7 ＜0.0001 0.07
Albumin† g/dL 4.1 3.955 4.4 ＜0.0001 ＜0.0001
Platelets† ×104/mm3 15.65 12.5 19.8 ＜0.0001 ＜0.0001
ALT† U/L 71 82 27 ＜0.0001 ＜0.0001
AST† U/L 57 68 25 ＜0.0001 ＜0.0001
AFP† ng/mL 5.4 11.8 3.1 ＜0.0001 ＜0.0001
†median (range)
Table 3　 Changes in laboratory data at 1 year after the start of Nucs treatment
All Nucs (n＝510) ETV (n＝397) LVD (n＝113)
p p p
T. Bil† mg/dL 　 0 (－26.7～＋1.3) ＜0.005 　 0 (－20.4～＋1.3) ＜0.01 －0.08 (－26.7～＋1.1) n.s.
Albumin† g/dL ＋0.25 (－0.9～＋2.2) ＜0.0001 ＋0.2 (－0.9～＋2.2) ＜0.0001 ＋0.4 (－0.4～＋2.1) ＜0.0001
Platelets† ×104/mm3 ＋0.5 (－22～＋13.1) n.s. ＋0.6 (－22～＋13.1) n.s. ＋0.5 (－7.3～＋11.2) n.s.
ALT† U/L －43 (－1,628～＋518) ＜0.0001 －42 (－1,628～＋518) ＜0.0001 －51 (－697～＋23) ＜0.0001
AST† U/L －28 (－1,439～＋140) ＜0.0001 －26 (－1,439～＋140) ＜0.0001 －37 (－507～＋37) ＜0.0001
AFP† ng/mL －1.3 (－989～＋240) ＜0.005 －1 (－989～＋240) ＜0.05 －7 (－650～＋0.8) ＜0.05
HBV DNA undetectable yes/no 85/262 ＜0.0001 85/194 ＜0.0001 0/68 ＜0.0001
HBsAg clearance yes/no 1/77 1/65 0/7
HBeAg clearance yes/no 15/87 10/69 5/18
This table shows the change from the baseline to 1 year after treatment.
†median (range). T. Bil,  total bilirubin; ALT,  alanine aminotransferase; AST,  aspartate aminotransferase; AFP,  alpha-fetoprotein;  
HBsAg,  hepatitis B surface antigen; HBeAg,  hepatitis B envelope antigen.  Other abbreviations are explained in the Table 1 footnote.
ment.  In contrast,  no patient in the LVD group 
reached the undetectable HBV DNA level.  Each Nucs 
showed eﬀective suppression of HBV reproduction.
　 Risk factors associated with HCC. We next 
analyzed all patients to search for the risk factors of 
hepatocarcinogenesis.  In the univariate analysis,  older 
age,  male sex,  higher serum total bilirubin,  lower 
serum albumin,  lower platelet count,  higher serum 
ALT,  higher serum AFP,  HBeAg positivity,  and 
higher serum HBV DNA were the risk factors for 
HCC development.  In the subsequent multivariate 
analysis,  higher age,  male sex,  a regimen not includ-
ing ETV,  lower serum albumin,  lower platelet count,  
HBeAg negativity,  and higher HBV DNA were the 
risk factors for hepatocarcinogenesis (Table 4).
　 However,  in the log-rank analysis,  the ETV group 
showed signiﬁcantly more HCC development compared 
to the Not-treated group (Fig. 1,  p＜0.005).  As 
shown in Table 2,  the ETV group was signiﬁcantly 
older,  with a signiﬁcantly higher proportion of males,  
and signiﬁcantly higher HBV DNA,  lower serum 
albumin,  higher serum ALT and higher serum AFP 
at baseline compared to the Not-treated group.  In this 
analysis,  we could not conﬁrm the eﬀect of ETV for 
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Table 4　 Risk factors for HCC in all patients (n＝1,206) in a proportional hazards model
Univariate Multivariate
Factors HR p HR p
Age 35 years 4.7 ＜0.001 - ＜0.005
Sex Male 1.4 n.s. 6.3 ＜0.001
ETV ＋ (vs. Not-treated) 1.2 n.s. 0.19 ＜0.001
T. Bil 1 mg/dL 1.6 0.n.s. 0.8 n.s.
Albumin ＜4 g/dL 3.4 ＜0.001 2.8 ＜0.05
Platelets ＜15×104/mm3 6.3 ＜0.001 5.2 ＜0.001
PT ＜90% 2.8 ＜0.005 1.2 n.s.
ALT 31 U/L 2.7 ＜0.001 0.26 n.s.
AFP 5 ng/mL 6.0 ＜0.001 2.2 n.s.
HBeAg ＋ 1.1 n.s. 0.32 ＜0.01
HBVDNA 5 log copies/mL 3.1 ＜0.001 6.5 ＜0.005
HCC,  hepatocellular carcinoma; HR,  hazard ratio; ETV,  entecavir; HBV,  hepatitis B virus; HR,  hazard ratio.
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Fig. 1　 Comparison of HCC cumulative incidence rates among the treatment groups in all patients (n＝1,206).  The cumulative HCC 
incident rate was signiﬁcantly lower in the Not-treated group compared to the ETV and LVD groups (log-rank test: p＜0.005 and p＜
0.0001,  respectively).  Black line: not treated.  Dotted line: ETV.  Gray line: LVD.
the suppression of hepatocarcinogenesis.
　 Subgroup analysis categorized by age, HBV 
DNA and HBeAg. To decrease the bias and to 
identify who should be treated with ETV,  we catego-
rized our cohort by age,  HBV DNA titer and HBeAg 
(Fig. 2).  The patients categorized in Group 1 (n＝
184) were characterized by age 35 years,  HBV 
DNA 4 log copies/mL,  and HBeAg positivity.  The 
patients in Group 2 (n＝237) were characterized by 
age 35 years,  HBV DNA 4 log copies/mL,  and 
HBeAg negativity.  The patients in Group 3 were 
characterized by age 35 years and HBV DNA＜4 log 
copies/mL.  The patients in Group 4 were＜35 years 
old.  As shown in Tables 5-8,  most of the diﬀerence 
in each parameter (age,  sex,  observation period,  
HBV DNA,  HBeAg,  T. Bil,  albumin,  platelets count,  
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<4 log copies/mL HBVDNA　≥4 log copies/mL 
Group 3
n=268
ETV=38 (HCC=0)
LVD=5 (2)
Not treated=225 (5)
≥35 yrs
Age
<35 yrs
Group 1
n=184
ETV=120 (HCC=5)
LVD=37 (10)
Not treated=27 (6)
Group 2
n=237
ETV=125 (HCC=14)
LVD=19 (9)
Not treated=93 (9)
Group 4
n=154
ETV=23 (HCC=0)
LVD=5 (0)
Not treated=126 (0)
Unclassiﬁed
 n=363
＋
HBe Ag
－
Fig. 2　 Categorization by age,  HBV DNA and HBeAg among all patients (n＝1,206).
Table 5　 Baseline parameters by Nucs treatment,  Group 1: age 35 years,  HBV DNA 4 log copies/mL and more,  and HBeAg positivity
ETV LVD Not-treated P (LVD vs.Not-treated)
P (ETV vs.
Not-treated)
No. of patients 120 37 27
Age† years 49 51 49 n.s. n.s.
Sex male/female 81/39 19/18 15/12 n.s. n.s.
Observation period† days 1,331 2,670 1,683 n.s. ＜0.05
HCC 5 10 6 n.s. ＜0.0005
HBV DNA† Log copies/mL 7.6 7.2 7.2 n.s. n.s.
HBV genotype B/C 2/85 0/19 0/10 n.s. n.s.
HBeAg ＋/－ 120/0 37/0 27/0 - -
T. Bil† mg/dL 0.7 0.9 0.84 n.s. n.s.
Albumin† g/dL 4 3.8 4.2 ＜0.005 ＜0.05
Platelets† ×104/mm3 15.3 11.8 15.3 ＜0.01 n.s.
ALT† U/L 79.5 64 52 ＜0.005 ＜0.005
AST† U/L 62 62 41 n.s. ＜0.005
AFP† ng/mL 9 13.2 5.2 ＜0.05 n.s.
†median (range).  Abbreviations are explained in earlier tablesʼ footnotes.
ALT,  AST,  AFP) between the 2 treatment groups 
was decreased after this categorization.
　 In Group 1,  120 patients were treated with ETV,  
37 were treated with LVD,  and 27 were non-treated 
patients.  In this group,  85.3  (157 patients) were 
treated with Nucs.  Age,  sex,  HBV DNA,  AFP were 
similar among these 3 treatment groups (Table 5).  We 
then compared the cumulative incidence of HCC.  As 
shown in Fig. 3,  HCC development was signiﬁcantly 
decreased in the ETV group (ETV vs. Not-treated 
p＜0.05,  ETV vs. LVD p＜0.01).
　 In Group 2,  the numbers of patients in the ETV,  
LVD and non-treated subgroups were 125,  19 and 93,  
respectively.  In this Group,  60.8  (n＝144) of the 
patients were treated with Nucs.  There were still 
signiﬁcant diﬀerences in age,  HBV DNA,  AFP and 
other biochemical parameters among the treatment 
groups (Table 6).  The HCC development was compa-
rable between the ETV group and the Not-treated 
group.  The LVD group developed HCC signiﬁcantly 
more frequently compared to the other groups (ETV 
vs. LVD,  p＜0.05; LVD vs. Not-treated,  p＜0.005).
　 In Group 3,  the numbers of patients in the ETV,  
LVD and non-treated subgroups were 38,  5 and 225,  
7Entecavir Reduces HepatocarcinogenesisFebruary 2016
Table 6　 Baseline parameters by Nucs treatment,  Group 2: age 35 years,  HBV DNA 4 log copies/mL and more,  and HBeAg negativity
ETV LVD Not-treated P (LVD vs.Not-treated)
P (ETV vs.
Not-treated)
No. of patients 125 19 93
Age† years 54 58 52 ＜0.005 ＜0.01
Sex male/female 69/56 15/4 46/47 ＜0.05 n.s.
Observation period† days 1,078 2,396 1,402 n.s. n.s.
HCC 14 9 9 0 n.s.
HBV DNA† Log copies/mL 6.3 6.6 4.9 ＜0.0001 ＜0.0001
HBV genotype A/B/C 2/3/68 0/1/5 1/8/28 n.s. ＜0.05
HBeAg ＋/－ 0/128 0/19 0/90 - -
T. Bil† mg/dL 0.8 1.01 0.8 ＜0.001 n.s.
Albumin† g/dL 4.1 4.1 4.4 ＜0.001 ＜0.0001
Platelets† ×104/mm3 14.8 13.4 18.9 ＜0.0001 ＜0.0001
ALT† U/L 70 88 28 ＜0.0001 ＜0.0001
AST† U/L 57 64.5 27 ＜0.0001 ＜0.0001
AFP† ng/mL 4.9 11.45 3 ＜0.005 ＜0.0001
†median (range)
Table 7　 Baseline parameters by Nucs treatment,  Group 3: age 35 years and HBV DNA lower than 4 log copies/mL
ETV LVD Not-treated P (LVD vs.Not-treated)
P (ETV vs.
Not-treated)
No. of patients 38 5 225
Age† Years 56 51 55 n.s. n.s.
Sex male/female 23/15 2/3 105/120 n.s. n.s.
Observation period† days 623 2,823 1,506 n.s. ＜0.0001
HCC 0 2 5 ＜0.01 n.s.
HBV DNA† Log copies/mL 3.15 2.6 3.3 n.s. n.s.
HBV genotype A/B/C 2/1/19 0/0/1 6/6/50 n.s. n.s.
HBeAg ＋/－ 3/22 2/2 4/205 ＜0.05 ＜0.01
T. Bil† mg/dL 0.62 1.01 0.7 n.s. n.s.
Albumin† g/dL 4.3 4.1 4.4 n.s. ＜0.05
Platelets† ×104/mm3 17.5 12.5 19.7 ＜0.05 n.s.
ALT† U/L 28 57 21 ＜0.005 ＜0.005
AST† U/L 34.5 53 23 ＜0.005 ＜0.0001
AFP† ng/mL 3.4 10 3 n.s. n.s.
†median (range)
respectively.  In this group,  only 16.0  (n＝43) of the 
patients were treated with Nucs and only seven 
patients developed HCC within the median observa-
tion period of 1,351.5 days.  The patientsʼ age,  sex,  
HBV DNA,  and AFP values were similar among the 
treatment groups (Table 7).  The HCC development 
was comparable between the ETV group and the Not-
treated group.  Because of the small number of 
patients,  the eﬀect of LVD was diﬃcult to assess.
　 In Group 4,  the numbers of patients in the ETV,  
LVD and non-treated subgroups were 23,  5 and 126,  
respectively (Table 8).  In this group,  only 18.2  (n
＝28) of the patients were treated with Nucs.  We 
could not assess the HCC development in this group,  
because no patient developed HCC within the median 
observation period of 1,889.5 days.  ETV signiﬁcantly 
suppressed hepatocarcinogenesis only in Group 1.
　 Propensity matched analysis by age, sex, 
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Fig. 3　 Comparison of the HCC cumulative incidence rates among each treatment group in Group 1 (n＝184), characterized by age
35 years, HBV DNA 4 log copies/mL,  and HBeAg positivity.  The log-rank test revealed a signiﬁcant diﬀerence between the ETV and 
Not-treated subgroups in the incidence of HCC (log-rank test: p＝0.0131).
Table 8　 Baseline parameters by Nucs treatment,  Group 4: ＜35 years old
ETV LVD Not-treated P (LVD vs.Not-treated)
P (ETV vs.
Not-treated)
No. of patients 23 5 126
Age† Years 32 30 30 n.s. n.s.
Sex male/female 19/4 5/0 71/55 n.s. ＜0.05
Observation period† days 1,813 3,039 1,876.5 ＜0.05 n.s.
HCC 0 0 0 -
HBV DNA† Log copies/mL ＞7.6 ＞7.6 5.5 n.s. ＜0.05
HBV genotype A/B/C 0/0/0 0/0/3 5/1/43 n.s. n.s.
HBeAg ＋/－ 15/7 5/0 61/62 ＜0.05 n.s.
T. Bil† mg/dL 0.8 0.75 0.7 n.s. n.s.
Albumin† g/dL 4.2 4 4.4 n.s. ＜0.005
Platelets† ×104/mm3 17.1 17.7 20.5 n.s. ＜0.05
ALT† U/L 208 329 31 ＜0.001 ＜0.0001
AST† U/L 102 99 25.5 ＜0.005 ＜0.0001
AFP† ng/mL 5.6 76.9 3 ＜0.05 ＜0.005
†median (range)
platelet count, ALT and serum HBV DNA.
We used propensity score matching in the ETV group 
and the Not-treated group by age,  sex,  platelet count,  
ALT and serum HBV DNA to eliminate the baseline 
bias,  resulting in a sample size of 148 patients per 
cohort (Table 9).  This operation also diminished the 
diﬀerences in AFP and HBeAg between these groups,  
but could not remove them because the patients who 
were treated with ETV were essentially at high risk 
for liver failure and HCC.  As shown in Fig. 4,  HCC 
development was signiﬁcantly decreased in the ETV 
group (p＜0.05).
　 We conducted the same analysis for the LVD 
group and the Not-treated group.  No signiﬁcant diﬀer-
ence was observed between these groups regarding 
hepatocarcinogenesis (Table 10,  Fig. 5,  p＞0.05).
Discussion
　 Our investigation revealed that long-term ETV 
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Fig. 4　 Comparison of HCC cumulative incidence rates between the ETV group and the Not-treated patients,  with propensity scores 
matched by age,  sex,  ALT,  Platelets count and HBV DNA.  HCC development was signiﬁcantly decreased in the ETV group (p＜0.05).
Table 9　 Baseline parameters by Nucs treatment (ETV group and Not-treated group),  propensity score matched by age,  sex,  ALT,  
Platelets count and HBV DNA
ETV Not-treated P
Propensity score† 0.96 0.96 n.s.
No. of patients 148 148
Age† years 53 48 n.s.
Sex male/female 91/57 91/57 n.s.
Observation period† days 1,144.5 1,439.5 n.s.
HCC 7 20 ＜0.01
T. Bil† mg/dL 0.7 0.8 ＜0.05
Albumin† g/dL 4.2 4.4 ＜0.0001
Platelets† ×104/mm3 17.5 17.8 n.s.
ALT† IU/L 46 42 n.s.
AFP† ng/mL 4.05 3.25 ＜0.05
HBV DNA† log copies/mL 5.5 5 n.s.
HBeAg ＋/－ 51/64 37/104 ＜0.005
†median (range)
therapy signiﬁcantly suppressed the hepatocarcinogen-
esis in CHB patients compared to CHB patients 
without Nucs treatment,  in a propensity matched 
analysis.  The eﬀect of ETV for HCC suppression was 
more evident among the patients who were 35 years 
old,  with HBV DNA 4 log copies/mL and positive 
HBe antigen at diagnosis.
　 Individuals who are chronically infected with HBV 
have a high risk of the development of HCC.  There 
are many reports about the HCC incidence rate in 
CHB patients.  The cumulative HCC incidence rates 
among Japanese Nucs-naïve HBV-infected patients 
were 2.1  at 5 years,  4.9  at 10 years,  and 18.8  
at 15 years [19].  In other studies,  the 5-year cumula-
tive HCC incidence rate of CHB patients was 3.3 ,  
and in patients with HBV-related cirrhosis,  the 5-year 
cumulative HCC incidence rate was 21.2-59  [20,  
21].
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Fig. 5　 Comparison of HCC cumulative incidence rates between the LVD group and the Not-treated patients, with propensity scores 
matched by age,  sex,  ALT,  Platelets count and HBV DNA.  No signiﬁcant diﬀerence was observed between these groups for hepatocar-
cinogenesis (p＞0.05).
Table 10 　Baseline parameters by Nucs treatment (LVD group and Not-treated group),  Propensity score matched by age,  sex,  ALT,  
Platelets count and HBV DNA
LVD Not-treated P
Propensity score† 0.79 0.79 n.s.
No. of patients 48 48
Age† years 51 52.5 n.s.
Sex male/female 26/22 26/22 n.s.
Observation period† days 2,829.5 1,333.5 ＜0.0005
HCC 12 14 n.s.
T. Bil† mg/dL 0.9 0.9 n.s.
Albumin† g/dL 4 4.3 ＜0.01
Platelets ×104/mm3 13.9 14 n.s.
ALT† IU/L 86 61 n.s.
AFP† ng/mL 11.5 5.1 ＜0.01
HBV DNA† log copies/mL 7.1 6.3 n.s.
HBeAg ＋/－ 29/12 20/24 ＜0.05
†median (range)
　 In the present study,  the cumulative HCC inci-
dence rates in the Nucs-naïve patients were 5  at 5 
years,  8.2  at 10 years,  and 20  at 20 years.  This 
result was comparable to the previous reports,  because 
our cohort contained cirrhosis patients.
　 In our cohort,  the multivariate analysis and the log-
rank test resulted in diﬀerent conclusions.  This is due 
to the baseline diﬀerences between the ETV group and 
the Not-treated group.  The ETV group was older and 
had a higher proportion of males,  high serum HBV 
DNA,  and poor hepatic reserve compared to the non-
treated patients.
　 We analyzed all patients to search for the risk 
factors of HCC development.  ETV treatment did not 
show a reduction of hepatocarcinogenesis.  Our study 
was retrospective,  and this ﬁnding is thus the result 
of strong selection bias.  We then categorized our 
cohort by age,  HBV DNA titer and HBeAg to remove 
the bias and to identify who should be treated with 
ETV.
　 Hosaka et al. reported that the eﬀect of ETV on 
HCC development was more prominent among patients 
with cirrhosis or at high risk by some scoring systems 
[22].  The diagnosis of cirrhosis is sometimes diﬃcult 
by less-invasive examinations (especially in chronic 
HBV infection),  though laparoscopic examination is 
useful for diagnosing cirrhosis and estimations of the 
risk of HCC development [6].  Such scoring systems 
would be complex.
　 Our categorization by age,  HBV DNA and HBeAg 
was easier and more objective to guide each treatment 
strategy.  As a result,  in Group 1,  the cumulative 
HCC incidence was signiﬁcantly reduced in the ETV-
treated patients compared to the LVD-treated patients 
and the non-treated patients (p＜0.05).  The patients 
in Group 1 had a high risk of HCC incidence,  and they 
should thus be treated with ETV.  In Group 2,  how-
ever,  the HCC incidence rate was lower than that of 
the Group 1 patients,  and the cumulative HCC inci-
dence was comparable among the ETV patients and the 
non-treated patients.  The patients who were younger 
or had lower HBV DNA levels (i.e.,  Groups 3 and 4) 
developed HCC very rarely.  Longer observation 
would be needed to assess these groups.
　 ETV showed a signiﬁcant beneﬁcial eﬀect in the 
present studyʼs focus on hepatocarcinogenesis,  espe-
cially in patients aged 35 years with HBV DNA 
levels 4 log copies/mL and positive HBe antigen at 
diagnosis.  The Nucs also increased the hepatic reserve 
(as shown in Table 3).  Further research is needed to 
assess the eﬀects associated with hepatic failure with 
HBV infection.
　 In conclusion,  in CHB patients aged 35 or older 
with an HBV DNA level 4 log copies/mL and posi-
tive HBe antigen at diagnosis,  ETV treatment is 
recommended for the suppression of HCC develop-
ment.
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